Orphan Synergy Europe - Pharma SA Aktie

5,52 EUR +0,52 EUR +10,40 %

14:12:45

STU

5,23 EUR -0,28 EUR -5,00 %

07.04.2025

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.114,29 Mio. EUR

KGV4,18Div. Rendite0,00%

WKNA14QXP

ISINFR0012127173

SymbolORPOF

Orphan Synergy Europe - Pharma SA Aktien News

Sortieren:Datum Meistgelesen

03.04.25GlobeNewswireOSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025

26.03.25GlobeNewswireOSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

11.03.25GlobeNewswireOSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

WerbungOrphan Synergy Europe - Pharma SA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

06.03.25GlobeNewswireOSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

24.02.25GlobeNewswireOSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

20.02.25GlobeNewswireOSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

29.01.25GlobeNewswireOSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

28.01.25GlobeNewswireOSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

13.01.25GlobeNewswireOSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

18.12.24GlobeNewswireOSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO

11.12.24GlobeNewswireOSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

02.12.24GlobeNewswireOSE Immunotherapeutics Strengthens Leadership and Executive Committee

04.11.24GlobeNewswireOSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

17.10.24GlobeNewswireOSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

26.09.24GlobeNewswireOSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

10.09.24GlobeNewswireOSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer

24.07.24GlobeNewswireOSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis

03.07.24GlobeNewswireBoehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

01.07.24GlobeNewswireOSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

24.06.24GlobeNewswireOSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

20.06.24GlobeNewswireOSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)

19.06.24GlobeNewswireOSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth

12.06.24GlobeNewswireOSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse

05.06.24GlobeNewswireOSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

30.05.24GlobeNewswireOSE Immunotherapeutics Provides Business and Corporate Update

22.05.24GlobeNewswireOSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

16.04.24GlobeNewswireOSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective

10.04.24GlobeNewswireOSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer

02.04.24GlobeNewswireOSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology

27.03.24GlobeNewswireOSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

27.03.24BusinesswireOSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

19.01.24BusinesswireOSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook

16.10.23BusinesswireOSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors

27.09.23BusinesswireOSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update

11.09.23BusinesswireOSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology

06.07.23BusinesswireOSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist:

04.07.23BusinesswireOSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment

20.06.23BusinesswireOSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer

15.06.23BusinesswireOSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences

26.05.23EQS GroupOSE Immunotherapeutics (OSE): Re-initiation Milestones anticipated throughout FY23

Orphan Synergy Europe - Pharma SA News

Orphan Synergy Europe - Pharma SA News: auf dieser Seite finden Sie alle Orphan Synergy Europe - Pharma SA News und Nachrichten zur Orphan Synergy Europe - Pharma SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Orphan Synergy Europe - Pharma SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Orphan Synergy Europe - Pharma SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.